TENIKAM

tenoxicam 20 mg

TENIKAM is a medicinal product from the group of non-steroidal anti-inflammatory drugs (NSAIDs) containing tenoxicam.

TENIKAM belongs to the oxicam class and provides pronounced analgesic, anti-inflammatory, and moderate antipyretic effects.

The mechanism of action of tenoxicam is based on inhibition of the cyclooxygenase (COX) enzyme, which catalyzes the conversion of arachidonic acid into prostaglandins both at the site of inflammation and in other body tissues. Tenoxicam also inhibits the formation of oxygen free radicals, suppresses phagocytosis and leukocyte chemotaxis, and exhibits antiplatelet properties. In addition to its peripheral anti-inflammatory action, tenoxicam also acts on the thalamic centers involved in pain perception. Tenoxicam is a non-selective cyclooxygenase inhibitor and acts equally on both COX-1 and COX-2 isoforms.

TENIKAM in the form of a lyophilisate is a long-acting medicinal product, with once-daily administration providing effective treatment. The mean plasma elimination half-life is approximately 72 hours. Following intravenous administration of 20 mg tenoxicam, plasma concentrations decrease rapidly during the first 2 hours due to distribution. After intramuscular injection, plasma levels reach at least 90% of the maximum concentration within 15 minutes. With the recommended dosage regimen of 20 mg once daily, steady-state plasma concentrations are achieved within 10–15 days.

Composition:

Active substance: tenoxicam.
Each vial contains 20 mg of tenoxicam.
Excipients: mannitol, disodium edetate, sodium metabisulfite (E223), trometamol, sodium hydroxide.
Each ampoule of solvent contains 2 mL of water for injections.

Dosage form:

Lyophilisate for solution for injection.

Appearance:

compact mass ranging in color from yellow to greenish-yellow.

Pharmacotherapeutic group:

Non-steroidal anti-inflammatory and antirheumatic products. Oxicams. Tenoxicam.
ATC code: M01AC02.

Shelf life:

3 years.

Storage conditions:

Store in the original packaging at a temperature not exceeding 25°C.
Keep out of the reach of children.

Incompatibility:

Unknown.

Packaging:

One vial containing lyophilisate and one ampoule containing solvent in a cardboard carton.

Prescription status:

Prescription only.

Manufacturer:

ANFARM HELLAS S.A.

Manufacturer’s location and address of the manufacturing site:

61st km Nat. Rd. Athens–Lamia, Schimatari Viotias, 32009, Greece.

For detailed information, please refer to the Instructions for Medical Use.

Information on medicinal products is intended exclusively for healthcare professionals.